To hear about similar clinical trials, please enter your email below
Trial Title:
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
NCT ID:
NCT06330012
Condition:
HER2-positive Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Screening
Masking:
None (Open Label)
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
GeoMx data analysis with clinical outcome
Description:
1. List of HER2 positive breast cancer
- Stage IV disease
- Treated with T-Dxd
- Available FFPE samples
2. Prepare tissue for digital spatial proteomics
- FFPE/H&E slide
- Region of Interest(ROI) check
- Make a Tissue microarray
- Prepare special slide for GeoMx
3. GeoMx data analysis with clinical outcome
Arm group label:
Spatial transcriptomic approch
Summary:
This study is the spatial transcriptomic approach for revealing the resistance mechanism
of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- HER2 positive breast cancer
- Stage IV disease
- Treated with T-Dxd
- Available FFPE samples
Exclusion Criteria:
- TNBC breast cancer
- Hormone receptor positive breast cancer
- Non-available FFPE samples
- Treated except T-Dxd
Gender:
Female
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Ji-Yeon Kim
Address:
City:
Seoul
Zip:
06351
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Ji-Yeon Kim
Phone:
82-2-3410-3459
Email:
jyeon25@skku.edu
Contact backup:
Last name:
MIRYOUNG HONG
Phone:
82-2-2148-7147
Email:
ring7629@naver.com
Start date:
March 18, 2024
Completion date:
December 31, 2027
Lead sponsor:
Agency:
Samsung Medical Center
Agency class:
Other
Source:
Samsung Medical Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06330012